Adapalene

證據等級: L5

預測適應症: 1 個

Adapalene: From Acne Vulgaris to Zinc, Elevated Plasma

One-Sentence Summary

Adapalene is a third-generation synthetic retinoid with established use in the topical treatment of acne vulgaris across multiple international markets. The TxGNN model predicts it may be effective for Zinc, Elevated Plasma, with no clinical trials and no publications currently supporting this direction. At present, this prediction is based solely on model output (TxGNN score: 99.51%), and substantial evidence gaps must be addressed before any clinical consideration.

Quick Overview

Item	Content
Original Indication	Acne vulgaris (topical retinoid therapy)
Predicted New Indication	Zinc, Elevated Plasma
TxGNN Prediction Score	99.51%
Evidence Level	L5
India Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Adapalene is a synthetic naphthoic acid derivative with selective retinoid activity. It binds preferentially to nuclear retinoic acid receptors RAR-β and RAR-γ, modulating gene expression programs involved in cellular differentiation, keratinization, and inflammatory cascades — which underlies its efficacy in acne.

A potential mechanistic bridge to zinc homeostasis exists through the well-documented interplay between retinoid signaling and zinc biology. Zinc is an indispensable structural cofactor for nuclear receptor zinc-finger domains, including those of the RAR/RXR superfamily through which Adapalene acts. Retinoids have been shown to regulate zinc-binding proteins (e.g., metallothioneins) and influence expression of zinc transporter genes (ZnT/ZIP families). If Adapalene modulates RAR-mediated transcriptional programs, downstream effects on zinc distribution and plasma levels are biologically conceivable.

It is important to note, however, that “zinc, elevated plasma” describes a laboratory finding rather than a discrete clinical disease entity. The therapeutic relevance of targeting this parameter with a topical retinoid — a drug with minimal systemic absorption — remains highly speculative in the absence of any supporting experimental or clinical data.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Adapalene is not currently marketed in India, with 0 registered products on record. No license entries are available for display.

Safety Considerations

Drug Interactions: A total of 58 potential drug interactions have been identified (source: DDInter). All interactions are currently classified as Unknown severity level, meaning risk magnitude has not been formally characterised. Clinically notable interacting drugs include:

Drug Class	Examples
Tetracycline antibiotics (commonly co-prescribed for acne)	Doxycycline, Tetracycline, Minocycline
Proton pump inhibitors	Pantoprazole, Omeprazole, Rabeprazole
Corticosteroids	Prednisone, Triamcinolone, Budesonide
Antifungals / Antimicrobials	Fluconazole, Metronidazole
Antihistamines	Cetirizine, Loratadine, Fexofenadine
Other	Clopidogrel, Ibuprofen, Bupropion, Scopolamine, Loperamide, Ranitidine

Please refer to the package insert for complete safety information, including warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score of 99.51%, there is currently zero supporting evidence from clinical trials or published literature (Evidence Level: L5). The predicted indication — “zinc, elevated plasma” — is a metabolic laboratory parameter rather than an established therapeutic target, and Adapalene’s minimal systemic bioavailability as a topical agent further limits plausibility for systemic zinc modulation.

To proceed, the following is needed:

Clarification of the clinical relevance of “zinc, elevated plasma” as a defined therapeutic target
Retrieval of full MOA data from DrugBank (DG002) to enable mechanistic linkage analysis
Retrieval of TFDA/CDSCO package insert to characterise warnings and contraindications (DG001)
Preclinical studies examining Adapalene’s effects on zinc transporter expression or metallothionein regulation
Assessment of systemic exposure levels achievable with topical versus any potential oral formulation, if systemic indication is pursued
Review of whether oral retinoids (e.g., isotretinoin) show any signal for plasma zinc modulation as a mechanistic proxy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.